The Spell Touch eye drop applicator is a revolutionary product designed to simplify and improve the application of eye drops. With its innovative design and features, this applicator aims to address common challenges faced by users, making the process easier and more effective. One of the main highlights of the Spell Touch eye drop applicator is its ergonomic design. The applicator is shaped to fit comfortably in the hand, allowing for a steady and controlled grip during application. This design feature enhances precision and reduces the risk of accidental spillage, ensuring that the eye drops are delivered exactly where they are needed. The Spell Touch eye drop applicator also incorporates a unique technology called "touch activation.
Using eyedrops past their expiration date can be problematic, as the ingredients in the drops may no longer work effectively.
Different kinds of eyedrops, especially prescription and non-prescription, may interact poorly if they are mixed and result in burning, stinging, or watery eyes. Different kinds of eyedrops, especially prescription and non-prescription, may interact poorly if they are mixed and result in burning, stinging, or watery eyes.
The Spell Touch eye drop applicator also incorporates a unique technology called "touch activation." This means that the applicator is activated and dispensing the eye drops only when it comes into contact with the eye. This eliminates wastage and allows for a more accurate dosage, as the eye drops are released precisely when the applicator touches the eye.
Latisse
Latisse (bimatoprost) Ophthalmic Solution is a synthetic prostaglandin analog used to treat patients with not enough or inadequate eyelashes. Latisse is also used to treat glaucoma.
What Are Side Effects of Latisse?
- eye redness or discomfort,
- eye itching,
- dry eyes,
- watery eyes, or eyelid redness, or puffy eyelids.
Other side effects of Latisse include hair growth on other areas of the skin where the medication frequently touches, and brown discoloration of the colored portion of the eye (iris) if used over months to years when the eye drop form is applied directly into the eyes to treat glaucoma.
Tell your doctor if you have serious side effects of Latisse including severe burning or itching of your eyes, severe redness or swelling in or around your eye, vision problems, eye pain, seeing halos around lights, oozing or discharge from your eye, or increased sensitivity to light.
Dosage for Latisse
Once nightly, place a one drop dose of Latisse 0.03% on the disposable sterile applicator supplied with the package and apply evenly along the skin of the upper eyelid margin at the base of the eyelashes. Blot excess solution runoff outside the upper eyelid margin with a tissue or absorbent cloth. Dispose of the applicator after one use. Repeat for the opposite eyelid margin using a new sterile applicator.
What Drugs, Substances, or Supplements Interact with Latisse?
Latisse may interact with glaucoma eye drops (such as bimatoprost, latanoprost, travoprost). Tell your doctor all medications and supplements you use.
Latisse During Pregnancy or Breastfeeding
During pregnancy, Latisse should be used only if prescribed. It is unknown if this drug passes into breast milk. Consult your doctor before breastfeeding.
Additional Information
Our Latisse (bimatoprost) Ophthalmic Solution Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.
Drug DescriptionDESCRIPTION
LATISSE ® (bimatoprost ophthalmic solution) 0.03% is a synthetic prostaglandin analog. Its chemical name is (Z)-7-[(1R,2R,3R,5S)-3,5-Dihydroxy-2-[(1E,3S)-3-hydroxy-5-phenyl-1-pentenyl]cyclopentyl]-N-ethyl-5- heptenamide, and its molecular weight is 415.58. Its molecular formula is C25H37NO4. Its chemical structure is:
Bimatoprost is a powder, which is very soluble in ethyl alcohol and methyl alcohol and slightly soluble in water. LATISSE ® is a clear, isotonic, colorless, sterile ophthalmic solution with an osmolality of approximately 290 mOsmol/kg.
Contains
Active: bimatoprost 0.3 mg/mL; Preservative: benzalkonium chloride 0.05 mg/mL; Inactives: sodium chloride; sodium phosphate, dibasic; citric acid; and purified water. Sodium hydroxide and/or hydrochloric acid may be added to adjust pH. The pH during its shelf life ranges from 6.8 - 7.8.
Indications & DosageINDICATIONS
LATISSE ® (bimatoprost ophthalmic solution) 0.03% is indicated to treat hypotrichosis of the eyelashes by increasing their growth including length, thickness and darkness.
DOSAGE AND ADMINISTRATION
Ensure the face is clean, makeup and contact lenses are removed. Once nightly, place one drop of LATISSE ® (bimatoprost ophthalmic solution) 0.03% on the disposable sterile applicator supplied with the package and apply evenly along the skin of the upper eyelid margin at the base of the eyelashes. The upper lid margin in the area of lash growth should feel lightly moist without runoff. Blot any excess solution runoff outside the upper eyelid margin with a tissue or other absorbent cloth. Dispose of the applicator after one use. Repeat for the opposite eyelid margin using a new sterile applicator.
Do not reuse applicators and do not use any other brush/applicator to apply LATISSE ® .
Do not apply to the lower eyelash line [see WARNINGS AND PRECAUTIONS and PATIENT INFORMATION].
Additional applications of LATISSE ® will not increase the growth of eyelashes.
Upon discontinuation of treatment, eyelash growth is expected to return to its pre-treatment level.
HOW SUPPLIED
Dosage Forms And Strengths
Ophthalmic solution containing bimatoprost 0.3 mg/mL.
Storage And Handling
LATISSE ® (bimatoprost ophthalmic solution) 0.03% is supplied sterile in opaque white low-density polyethylene dispenser bottles and tips with turquoise polystyrene caps accompanied by sterile, disposable applicators:
3 mL in a 5 mL bottle with 70 applicators NDC 0023-3616-70
5 mL in a 5 mL bottle with 140 applicators NDC 0023-3616-05
Storage: Store at 2° to 25°C (36° to77°F).
Distributed by: Allergan USA, Inc.Madison, NJ 07940. Revised: Aug 2021
Side Effects & Drug InteractionsSIDE EFFECTS
The following adverse reactions are described elsewhere in the labeling:
- Effects on Intraocular Pressure [see WARNINGS AND PRECAUTIONS]
- Iris Pigmentation [see WARNINGS AND PRECAUTIONS]
- Lid Pigmentation [see WARNINGS AND PRECAUTIONS]
- Hair Growth Outside the Treatment Area [see WARNINGS AND PRECAUTIONS]
- Intraocular Inflammation [see WARNINGS AND PRECAUTIONS]
- Macular Edema [see WARNINGS AND PRECAUTIONS]
- Hypersensitivity [see CONTRAINDICATIONS]
Clinical Trial Experience
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
The following information is based on clinical trial results from a multicenter, double-masked, randomized, vehicle-controlled, parallel study including 278 adult patients for four months of treatment.
The most frequently reported adverse reactions were eye pruritus, conjunctival hyperemia, skin hyperpigmentation, ocular irritation, dry eye symptoms, and periorbital erythema. These reactions occurred in less than 4% of patients. Additional adverse reactions seen in clinical trials experience include foreign body sensation, hair growth abnormal, and iris hyperpigmentation.
Additional adverse reactions reported with bimatoprost ophthalmic solution (LATISSE ® ) for the reduction of intraocular pressure include, ocular dryness, visual disturbance, ocular burning, eye pain, blepharitis, cataract, superficial punctate keratitis, eye discharge, tearing, photophobia, allergic conjunctivitis, asthenopia, conjunctival edema, iritis, infections (primarily colds and upper respiratory tract infections), headaches, and asthenia.
Postmarketing Experience
The following adverse reactions have been identified during postapproval use of LATISSE ® . Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. The reactions include dry skin of the eyelid and/or periocular area, eye swelling, eyelid edema, hordeolum, hypersensitivity (local allergic reactions), lacrimation increased, madarosis and trichorrhexis (temporary loss of a few lashes to loss of sections of eyelashes, and temporary eyelash breakage, respectively), periorbital and lid changes associated with periorbital fat atrophy and skin tightness resulting in deepening of eyelid sulcus and eyelid ptosis, rash (including macular and erythematous), skin discoloration (periorbital), skin exfoliation of the eyelid and/or periorbital area, trichiasis, and vision blurred.
DRUG INTERACTIONS
No Information Provided
Warnings & PrecautionsWARNINGS
Included as part of the "PRECAUTIONS" Section
PRECAUTIONS
Effects On Intraocular Pressure
Bimatoprost ophthalmic solution (LUMIGAN ® ) lowers intraocular pressure (IOP) when instilled directly to the eye in patients with elevated IOP. In clinical trials, in patients with or without elevated IOP, LATISSE ® lowered IOP, however, the magnitude of the reduction was not cause for clinical concern.
In ocular hypertension studies with LUMIGAN ® , it has been shown that exposure of the eye to more than one dose of bimatoprost daily may decrease the intraocular pressure lowering effect. In patients using LUMIGAN ® or other prostaglandin analogs for the treatment of elevated intraocular pressure, the concomitant use of LATISSE ® may interfere with the desired reduction in IOP. Patients using prostaglandin analogs including LUMIGAN ® for IOP reduction should only use LATISSE ® after consulting with their physician and should be monitored for changes to their intraocular pressure.
Iris Pigmentation
Increased iris pigmentation has occurred when bimatoprost solution was administered. Patients should be advised about the potential for increased brown iris pigmentation which is likely to be permanent [see ADVERSE REACTIONS] .
The pigmentation change is due to increased melanin content in the melanocytes rather than to an increase in the number of melanocytes. The long term effects of increased pigmentation are not known. Iris color changes seen with administration of bimatoprost ophthalmic solution may not be noticeable for several months to years. Typically, the brown pigmentation around the pupil spreads concentrically towards the periphery of the iris and the entire iris or parts of the iris become more brownish. Neither nevi nor freckles of the iris appear to be affected by treatment. Treatment with LATISSE ® solution can be continued in patients who develop noticeably increased iris pigmentation.
Lid Pigmentation
Bimatoprost has been reported to cause pigment changes (darkening) to periorbital pigmented tissues and eyelashes. The pigmentation is expected to increase as long as bimatoprost is administered, but has been reported to be reversible upon discontinuation of bimatoprost in most patients.
Hair Growth Outside The Treatment Area
There is the potential for hair growth to occur in areas where LATISSE ® solution comes in repeated contact with the skin surface. It is important to apply LATISSE ® only to the skin of the upper eyelid margin at the base of the eyelashes using the accompanying sterile applicators, and to carefully blot any excess LATISSE ® from the eyelid margin to avoid it running onto the cheek or other skin areas.
Intraocular Inflammation
LATISSE ® solution should be used with caution in patients with active intraocular inflammation (e.g., uveitis) because the inflammation may be exacerbated.
Macular Edema
Macular edema, including cystoid macular edema, has been reported during treatment with bimatoprost ophthalmic solution (LUMIGAN ® ) for elevated IOP. LATISSE ® should be used with caution in aphakic patients, in pseudophakic patients with a torn posterior lens capsule, or in patients with known risk factors for macular edema.
Contamination Of LATISSE ® Or Applicators
The LATISSE ® bottle must be kept intact during use. It is important to use LATISSE ® solution as instructed, by placing one drop on the single-use-per-eye applicator. The bottle tip should not be allowed to contact any other surface since it could become contaminated. The accompanying sterile applicators should only be used on one eye and then discarded since reuse of applicators increases the potential for contamination and infections. There have been reports of bacterial keratitis associated with the use of multiple-dose containers of topical ophthalmic products [see PATIENT INFORMATION].
Use With Contact Lenses
LATISSE ® contains benzalkonium chloride, which may be absorbed by and cause discoloration of soft contact lenses. Contact lenses should be removed prior to application of solution and may be reinserted 15 minutes following its administration.
Patient Counseling Information
Advise the patient to read the FDA-approved patient labeling (PATIENT INFORMATION).
Nightly Application
Inform patients that LATISSE ® (bimatoprost ophthalmic solution) should be applied every night using only the accompanying sterile applicators. They should start by ensuring their face is clean, all makeup is removed, and their contact lenses removed (if applicable). Then, carefully place one drop of LATISSE ® solution on the disposable sterile applicator and brush cautiously along the skin of the upper eyelid margin at the base of the eyelashes. If any LATISSE ® solution gets into the eye proper, it will not cause harm. The eye should not be rinsed.
Additional applications of LATISSE ® will not increase the growth of eyelashes.
Inform patients not to apply to the lower eyelash line. Any excess solution outside the upper eyelid margin should be blotted with a tissue or other absorbent material.
The onset of effect is gradual but is not significant in the majority of patients until 2 months. Counsel patients that the effect is not permanent and can be expected to gradually return to the original level upon discontinuation of treatment with LATISSE ® .
Handling The Bottle And Applicator
Instruct patients that the LATISSE ® bottle must be maintained intact and to avoid allowing the tip of the bottle or applicator to contact surrounding structures, fingers, or any other unintended surface in order to avoid contamination of the bottle or applicator by common bacteria known to cause ocular infections. Instruct patients to only use the applicator supplied with the product once and then discard since reuse could result in using a contaminated applicator. Serious infections may result from using contaminated solutions or applicators.
Potential For Intraocular Pressure Effects
LATISSE ® may lower intraocular pressure although not to a level that will cause clinical harm.
In patients using LUMIGAN ® or other prostaglandin analogs for the treatment of elevated intraocular pressure, the concomitant use of LATISSE ® may interfere with the desired reduction in IOP. Patients using prostaglandin analogs for IOP reduction should only use LATISSE ® after consulting with their physician.
Potential For Eyelid Skin Darkening
Inform patients about the possibility of eyelid skin darkening, which may be reversible after discontinuation of LATISSE ® .
Potential For Iris Darkening
Advise patients about the potential for increased brown iris pigmentation which is likely to be permanent.
Increased iris pigmentation has occurred when bimatoprost solution was administered.
Potential For Unexpected Hair Growth Or Eyelash Changes
Inform patients of the possibility of hair growth occurring outside of the target treatment area if LATISSE ® repeatedly touches the same area of skin outside the treatment area. They should also be informed of the possibility of disparity between eyes in length, thickness, pigmentation, number of eyelashes or vellus hairs, and/or direction of eyelash growth. Eyelash changes are likely reversible upon discontinuation of treatment.
When To Seek Physician Advice
Advise patients that if they develop a new ocular condition (e.g., trauma or infection), experience a sudden decrease in visual acuity, have ocular surgery, or develop any ocular reactions, particularly conjunctivitis and eyelid reactions, they should immediately seek their physician’s advice concerning the continued use of LATISSE ® . Patients on IOP-lowering medications should not use LATISSE ® without prior consultation with their physician.
Contact Lens Use
Advise patients that LATISSE ® solution contains benzalkonium chloride, which may be absorbed by and cause discoloration of soft contact lenses. Contact lenses should be removed prior to application of LATISSE ® and may be reinserted 15 minutes following its administration.
Nonclinical Toxicology
Carcinogenesis, Mutagenesis, Impairment Of Fertility
Carcinogenesis
Bimatoprost was not carcinogenic in either mice or rats when administered by oral gavage for 104 weeks at doses up to 2 mg/kg/day and 1 mg/kg/day, respectively (192 and 291 times the human systemic exposure following topical ophthalmic administration of bimatoprost 0.03% to the cornea or conjunctival sac bilaterally once daily based on blood AUC levels).
Mutagenesis
Bimatoprost was not mutagenic or clastogenic in the Ames test, in the mouse lymphoma test, or in the in vivo mouse micronucleus tests.
Impairment Of Fertility
Bimatoprost did not impair fertility in male or female rats up to doses of 0.6 mg/kg/day (103 times the human systemic exposure following topical ophthalmic administration of bimatoprost 0.03% to the cornea or conjunctival sac bilaterally once daily based on blood AUC levels).
Use In Specific Populations
Pregnancy
Risk Summary
There are no adequate and well-controlled studies of LATISSE ® (bimatoprost ophthalmic solution) 0.03% administration in pregnant women. There is no increase in the risk of major birth defects or miscarriages based on bimatoprost postmarketing experience.
In embryofetal development studies, administration of bimatoprost to pregnant mice and rats during organogenesis resulted in abortion and early delivery at oral doses at least 33 times (mice) or 94 times (rats) the human exposure following topical ophthalmic administration of bimatoprost 0.03% to the cornea or conjunctival sac bilaterally once daily, based on the area under the curve (AUC). These adverse effects were not observed at 2.6 times (mice) and 47 times (rats) the human exposure following topical ophthalmic administration of bimatoprost 0.03% to the cornea or conjunctival sac bilaterally once daily, based on AUC.
In pre/postnatal development studies, administration of bimatoprost to pregnant rats from organogenesis to the end of lactation resulted in reduced gestation length and fetal body weight, and increased fetal and pup mortality at oral doses at least 41 times the human systemic exposure following topical ophthalmic administration of bimatoprost 0.03% to the cornea or conjunctival sac bilaterally once daily, based on AUC. No adverse effects were observed in rat offspring at exposures estimated at 14 times the human exposure following topical ophthalmic administration of bimatoprost 0.03% to the cornea or conjunctival sac bilaterally once daily, based on AUC.
Because animal reproductive studies are not always predictive of human response LATISSE ® 0.03% should be administered during pregnancy only if the potential benefit justifies the potential risk to the fetus.
Data
Animal Data
In an embryofetal development rat study, abortion was observed in pregnant rats administered bimatoprost orally during organogenesis at 0.6 mg/kg/day (94 times the human systemic exposure following topical ophthalmic administration of bimatoprost 0.03% to the cornea or conjunctival sac bilaterally once daily, based on AUC). The No Observed Adverse Effect Level (NOAEL) for abortion was 0.3 mg/kg/day (estimated at 47 times the human systemic exposure following topical ophthalmic administration of bimatoprost 0.03% to the cornea or conjunctival sac bilaterally once daily based on AUC). No abnormalities were observed in rat fetuses at doses up to 0.6 mg/kg/day.
In an embryofetal development mouse study, abortion and early delivery were observed in pregnant mice administered bimatoprost orally during organogenesis at doses greater than or equal to 0.3 mg/kg/day (33 times the human systemic exposure following topical ophthalmic administration of bimatoprost 0.03% to the cornea or conjunctival sac bilaterally once daily, based on AUC). The NOAEL for abortion and early delivery was 0.1 mg/kg/day (2.6 times the human systemic exposure following topical ophthalmic administration of bimatoprost 0.03% to the cornea or conjunctival sac bilaterally once daily, based on AUC). No abnormalities were observed in mouse fetuses at doses up to 0.6 mg/kg/day (72 times the human systemic exposure following topical ophthalmic administration of bimatoprost 0.03% to the cornea or conjunctival sac bilaterally once daily, based on AUC).
In a pre/postnatal development study, treatment of pregnant rats with bimatoprost orally from gestation day 7 to lactation day 20 resulted in reduced gestation length, increased late resorptions, fetal deaths, and postnatal pup mortality, and reduced pup body weight at doses greater than or equal to 0.3 mg/kg/day. These effects were observed at exposures at least 41 times the human systemic exposure following topical ophthalmic administration of bimatoprost 0.03% to the cornea or conjunctival sac bilaterally once daily, based on AUC. The NOAEL for postnatal development and mating performance of the offspring was 0.1 mg/kg/day (estimated at 14 times the human systemic exposure following topical ophthalmic administration of bimatoprost 0.03% to the cornea or conjunctival sac bilaterally once daily, based on AUC).
Lactation
Risk Summary
It is not known whether topical ocular treatment with LATISSE ® 0.03% could result in sufficient systemic absorption to produce detectable quantities in human milk. In animal studies, bimatoprost has been shown to be present in breast milk of lactating rats at an intravenous dose (i.e., 1 mg/kg) 324 times the recommended human ophthalmic dose (on a mg/m2 basis), however no animal data is available at clinically relevant doses.
The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for LATISSE ® 0.03% and any potential adverse effects on the breastfed child from LATISSE ® 0.03%.
Pediatric Use
Use of LATISSE ® was evaluated in a sixteen-week double-masked, randomized, vehicle-controlled study conducted in pediatric patients who were post-chemotherapy or had alopecia areata, and adolescents who had hypotrichosis with no associated medical condition. No new safety issues were observed. The results of the Global Eyelash Assessment (GEA) are provided in Table 1.
Table 1. Number (%) of subjects with at least a 1-grade increase from baseline at month 4 in Global Eyelash Assessment
| Age Range (years) | LATISSE ® | Vehicle | Difference (95% CI) | |
| Adolescents with hypotrichosis (N=40) | 15 - 17 | 19/26 (73%) | 1/14 (7%) | 66% (44%, 88%) |
| Post Chemotherapy Pediatric Patients (N=16) | 5 - 17 | 11/13 (85%) | 3/3 (100%) | -15% (-35%, 4%) |
| Alopecia Areata Pediatric Patients (N=15) | 5 - 17 | 4/9 (44%) | 2/6 (33%) | 11% (-39%, 61%) |
Geriatric Use
No overall clinical differences in safety or effectiveness have been observed between elderly and other adult patients.
Ensure the face is clean, makeup and contact lenses are removed. Once nightly, place one drop of LATISSE ® (bimatoprost ophthalmic solution) 0.03% on the disposable sterile applicator supplied with the package and apply evenly along the skin of the upper eyelid margin at the base of the eyelashes. The upper lid margin in the area of lash growth should feel lightly moist without runoff. Blot any excess solution runoff outside the upper eyelid margin with a tissue or other absorbent cloth. Dispose of the applicator after one use. Repeat for the opposite eyelid margin using a new sterile applicator.
Furthermore, the Spell Touch eye drop applicator is designed with hygiene in mind. The container that holds the eye drops is made of sterile materials, protecting the solution from contamination. The applicator itself is also easy to clean and maintain, reducing the risk of bacterial growth and ensuring a safe and hygienic application. Overall, the Spell Touch eye drop applicator offers several advantages over traditional methods of eye drop application. Its ergonomic design, touch activation technology, and focus on hygiene make it a convenient and reliable tool for anyone needing to administer eye drops. By improving the accuracy and ease of application, this applicator strives to enhance the overall experience and effectiveness of using eye drops..
Reviews for "Finding the right eye drops for use with the spell touch eye drop applicator"
1. Amanda - 2 stars - I was really disappointed with the Spell touch eye drop applicator. It was incredibly difficult to use and seemed to make a mess every time I tried to use it. The applicator is supposed to make it easier to administer eye drops, but I found it to be more frustrating than anything. It didn't distribute the drops evenly and often caused them to spill out of my eyes. I ended up wasting a lot of product because of this. I wouldn't recommend this eye drop applicator to anyone.
2. Jason - 1 star - The Spell touch eye drop applicator was a complete waste of my money. It is poorly designed and doesn't function as advertised. The applicator tip is too flimsy and doesn't hold the eye drops properly, resulting in inconsistent and uneven distribution. I also found it difficult to squeeze the bottle to dispense the eye drops. Overall, this product is a total fail and I regret purchasing it.
3. Sarah - 2 stars - I had high hopes for the Spell touch eye drop applicator, but it ended up being a disappointment. The applicator is bulky and uncomfortable to use. It was difficult to get the drops into my eyes without them spilling all over my face. Additionally, the applicator tip didn't seem to provide a precise and gentle application as advertised. I ended up resorting to using the traditional eye drop bottle instead. Don't waste your money on this gimmicky product.